LAB282 | ACCELERATING OXFORD DRUG DISCOVERY

Case
Study
One

Myelofibrosis

DISCOVERING GROUND-BREAKING THERAPIES FROM OXFORD UNIVERSITY

Case
Study
One

Myelofibrosis

DISCOVERING GROUND-BREAKING THERAPIES FROM OXFORD UNIVERSITY

Case
Study
Two

Myocarditis

Ground breaking research from Oxford University

Case
Study
Two

Myocarditis

Ground breaking research from Oxford University

Case
Study
Three

Next Generation Antibiotics

Ground breaking research from Oxford University

Case
Study
Three

Next Generation Antibiotics

Ground breaking research from Oxford University

ACCELERATING OXFORD DRUG DISCOVERY

Recently expanded and open for new calls

37 projects funded

DISCOVER MORE >

ACCELERATING OXFORD DRUG DISCOVERY

Recently expanded and open for new calls

37 projects funded

DISCOVER MORE >

ACCELERATING OXFORD DRUG DISCOVERY

Recently expanded and open for new calls

37 projects funded

DISCOVER MORE >|

LAB282 welcomes ad hoc applications, as well as applications in response to specific calls that it may issue.

LAB282 helps academics access a wide range of early stage drug discovery and development capabilities.

Thomas Hanke, our Expert in Residence, works in cross-functional teams setting directions and fostering innovation.